Related Experiment Video
Updated: Jul 16, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial
M Praga1, V Barrio, G Fernández Juárez
1Servicio de Nefrología, Hospital 12 de Octubre, Madrid, Spain. mpragat@senefro.org
Kidney International
|March 23, 2007
Summary
Tacrolimus monotherapy effectively treats membranous nephropathy, a common cause of nephrotic syndrome. This immunosuppressant significantly increases remission rates and reduces the risk of kidney function decline in adults.
Area of Science:
- Nephrology
- Immunosuppression Therapy
Background:
- Membranous nephropathy frequently causes nephrotic syndrome in adults.
- Spontaneous remission occurs in some cases, but many experience progressive renal dysfunction.
Purpose of the Study:
- To evaluate tacrolimus monotherapy for achieving remission in biopsy-proven membranous nephropathy.
- To assess the impact of tacrolimus on proteinuria and renal function preservation.
Main Methods:
- Prospective randomized trial involving 48 patients with membranous nephropathy.
- Treatment group received tacrolimus (0.05 mg/kg/day) for 12 months with a 6-month taper.
- Control group received standard care.
Main Results:
- Remission probabilities were 58%, 82%, and 94% at 6, 12, and 18 months in the tacrolimus group versus 10%, 24%, and 35% in the control group.
- Tacrolimus significantly reduced proteinuria and the risk of a 50% increase in serum creatinine.
- No relapses occurred during the tacrolimus taper, though nephrotic syndrome recurred in ~50% after withdrawal.
Conclusions:
- Tacrolimus is a highly effective therapeutic option for membranous nephropathy with preserved renal function.
- It offers significant remission rates and reduces the risk of renal function deterioration.
- Long-term efficacy and relapse patterns post-withdrawal warrant further investigation.
